Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci142 in healthy Chinese women
NCT07302035Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of human lysozyme in bacterial vaginosis (BV), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Percentage of participants with adverse events at 15 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
human lysozyme
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT07302035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302035.